Bilirubin/rat serum albumin interaction

Area of Science:

• Biochemistry
• Physiology
• Neonatal Medicine

Background:

• Bilirubin, a byproduct of red blood cell breakdown, can cause brain damage (kernicterus) in newborns if its levels are too high.
• Understanding bilirubin binding to serum proteins is crucial for developing effective treatments for neonatal jaundice.
• Rats are often used as animal models to study bilirubin metabolism and its effects.

Purpose of the Study:

• To investigate and highlight the essential differences in bilirubin binding between rat and human serum proteins.
• To compare the competitive binding of bilirubin and N-[4-[(4-aminophenyl)-sulfonyl]phenyl]-acetamide (MADDS) to albumin in both species.
• To assess the impact of albumin binding on bilirubin oxidation rates in rats versus humans.

Main Methods:

• Acidimetric titration was used to determine the number of hydrogen ions released during bilirubin binding to rat and human serum.
• Competitive binding assays were performed using bilirubin and MADDS with rat and human serum albumin.
• The rate of bilirubin oxidation by hydrogen peroxide and peroxidase was measured in the presence of rat and human serum albumin.

Main Results:

• Bilirubin binding to rat serum proteins releases less than one hydrogen ion per molecule, indicating binding of bilirubin acid.
• Bilirubin binding to human serum proteins releases two hydrogen ions, signifying binding of the bilirubin dianion.
• MADDS binding to rat serum albumin is only slightly affected by bilirubin, while they compete for binding sites on human serum albumin.
• Rat serum albumin moderately decreases bilirubin oxidation, whereas human serum albumin strongly protects bilirubin from oxidation.

Conclusions:

• Significant biochemical and binding differences exist between rat and human serum proteins concerning bilirubin.
• These disparities challenge the direct translation of rat model findings to human neonatal conditions.
• Caution is advised when extrapolating results from rat models to human neonates for preventing bilirubin encephalopathy.